PIN96 Predicting the Impact of Adverse Events and Treatment Duration on Medical Resource Utilisation Related Costs in Hepatitis C Genotype 1 Treatment-Naïve Patients Receiving Antiviral Therapy  by Akpo, H. et al.
A680  VA L U E  I N  H E A LT H  1 7  ( 2 0 1 4 )  A 3 2 3 – A 6 8 6  
had STD data and 1,985 had LTD data during year following diagnosis. Of these 
87% had at least one day of ABS, 21% at least one STD claim and 2% at least one 
LTD claim. Total ABS costs in the year following the HCV diagnosis were $17,439. 
Among those with claims, STD costs during year following diagnosis were $42,149 
and LTD costs were $50,422. A smaller subset of patients had productivity data 
available for the 2 year period following diagnosis (n= 215 [ABS], n= 748 [STD], n= 670 
[LTD]). Costs during year 2 were similar to first year cost- approximately $21,400 for 
ABS, $42,700 for STD and $55,500 for LTD. ConClusions: Novel treatments can be 
costly but potential reductions in productivity losses may offset these costs. Payers 
should consider broad and long-term impact of these medications when making 
reimbursement decisions.
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objeCtives: Patients treated with triple therapy regimens of a protease inhibi-
tor (PI), pegylated interferon and ribavirin, require monitoring to assess treatment 
response (HCV-RNA assays) and determine adverse event development (clinical 
review and laboratory tests). The aim of this study was to examine resource uti-
lisation associated with treatment of patients with HCV genotype-1 managed in 
an ambulatory hospital-based setting. Methods: Data on resource utilisation for 
patients prospectively enrolled in the Irish Hepatitis C Outcomes and Research 
network (ICORN) Treatment Registry, who reached end of treatment (EOT) were gath-
ered. Data on 1) attendances to outpatient clinics for clinical assessment, 2) labora-
tory tests (FBC, liver profile etc.) and 3) HCV-RNA assays were quantified. Results: 
A total of 50/241 patients have reached EOT to date. Telaprevir accounts for 36 
patients, of whom 30% fulfilled criteria for response guided therapy (RGT), while 29% 
of boceprevir-treated patients fulfilled criteria. A total of 1371 outpatient clinic visits 
were recorded for patients to EOT (mean 29.3 (range 10-51) (SD = 9)). There were 3481 
individual laboratory tests undertaken. A full blood count is the most commonly 
ordered investigation, n= 1179 (costs incurred € 18,864). A total of 382 HCV-RNA PCR 
assays were completed to EOT (mean of 7.10 (range 4-11 (SD = 2)) per patient. This 
was 250 in excess of expected numbers of HCV-RNA assays from SPC instruction. It 
was estimated that adherence to mandated HCV-RNA assays would result in cost 
savings of approximately € 9,000 or € 180 per patient treated. ConClusions: There 
is significant resource utilisation associated with the treatment of HCV patients in a 
hospital-based setting. Cost savings may be generated by the development of guid-
ance on laboratory monitoring, and careful adherence to decision rule time points. 
This may have implications for guideline development for monitoring of patients 
treated with new agents for HCV in the near future.
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objeCtives: To estimate the direct costs of HCV management for genotype 1 
patients throughout their lifetime based on the natural history of the disease from 
payer perspective in Colombia. Methods: Direct costs were estimated from a payer 
perspective by using a micro-costing approach of all relevant resources used to 
manage patients with HCV genotype 1 since the diagnosis for a lifetime perspective. 
Resources and clinical practice were identified, measured and valued for nine health 
states. Resource use and clinical patterns were validated with a panel of experts in 
managing HCV patients by applying a comprehensive survey. Each of the resources 
was valued based on standard national public lists of fees in Colombian pesos (when 
the list of fees was released? Is it up to date or not?). Total costs for each of the health 
states of the disease were calculated for a one year time horizon. Results: Direct 
cost were presented in US Dollars using the average year to date exchange rate (USD 
1 = COP 1,974). Estimated average direct cost for each health state per year: non 
diagnostic HCV (USD 512), chronic HCV F0-F3 (USD 1,440), compensated cirrhosis 
(USD 976), decompensated cirrhosis (USD 10,782), hepatocellular carcinoma (USD 
10,263), liver transplantation (USD 28,883), post-transplant (USD 1,933), monitoring 
drug therapy for HCV and the management of adverse events (USD 1,020), death 
(USD 15,538). ConClusions: Chronic HCV infection represents an important eco-
nomic and humanistic burden for health systems in the world. This micro-costing 
study provides valuable information for further economic cost of illness analysis 
from the Colombian payers setting. It also reflects severity and economic impact 
of HCV related health states.
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objeCtives: Studies on medical resource utilization (MRU) and related costs are 
important for evaluating the potential patient management and cost-effectiveness 
implications of antiviral treatments for Hepatitis C virus (HCV) infection. The objec-
tives of this study were (i) to compare the MRU and related costs for two treatment 
approaches, (ii) to identify the main drivers of resource use and costs, and (iii) to 
assess the effect of various treatment regimen attributes on MRU-related costs 
in a UK clinical setting. Methods: The analysis used data collected alongside 
the simeprevir (SMV) phase III trials for treatment-naïve genotype 1 HCV-infected 
patients; these data covered outpatient consultations with specialists, emergency 
The potential cost savings were summarised for a single patient and up-scaled for 
Switzerland. Results: They are estimated to add up to approximately 9 Mio CHF 
for Switzerland for all three scenarios. Scenario 2 contributed most with about 6.5 
Mio CHF (70%). For a single patient potential savings of about 10k CHF resulted for 
scenario 1 and 700k CHF for scenarios 2 and 3. The major share of potential savings 
accrues from adjusted antibiotic treatment and from avoidance of productivity 
losses. ConClusions: Even though these results are preliminary and partly based 
on assumptions, it is expected that the economic advantages are still attractive even 
when savings might be partly lower. Nevertheless, it is desirable to verify assump-
tions and potentials by clinical trials and pilot studies.
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objeCtives: Vaccination is the best way to prevent from life-threatening and 
debilitating infectious diseases that still lead to a huge epidemiological and eco-
nomic burden to societies. The French health authorities have recently decided 
to implement a “rendez-vous” in the vaccination calendar for individuals aged 65 
years old, to achieve optimal vaccination coverage rates and improve protection for 
elderly population against diphtheria, tetanus, seasonal influenza, pneumococcal 
diseases, pertussis and herpes zoster. The objective of this study was to assess from 
a governmental perspective the return on investment of the 65 year-old’ “rendez-
vous vaccinal” in France. Methods: A cohort model was developed to compare 
the mortality, morbidity, lifetime earnings and transfers of a cohort aged 65 with 
or without vaccination. The incremental total discounted lifetime direct and indi-
rect tax revenue gained, the reduction in direct medical and social insurance costs 
resulting from the vaccinations were estimated and compared to vaccination budg-
ets. Uncertainty was handled using univariate sensitivity analyses on vaccination 
coverage, epidemiological data, economic parameters and discount rates. Results: 
From the French government’s point of view, vaccinating individuals aged 65 years 
old age is estimated to produce favorable benefit cost-ratios [~1 up to 3]. The results 
suggest that every euro invested in vaccination is expected to at-least be paid back 
to the government due to increased tax revenues, social insurance and health care 
cost-savings. ConClusions: This macro-economic analysis approaches vaccina-
tion as an investment rather than a cost. From the French Government’s point of 
view, promoting actively vaccination for 65 year-old individuals in France will favor 
healthy ageing while producing positive returns on investment.
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objeCtives: While the life expectancy of timely antiretrovirally treated HIV 
infected adults converges to that of the general population, there are still imbal-
ances with regard to the labor market [Worthington et al. (2011); Dray-Spira et 
al. (2008); Rabkin et al. (2004); Goldman, Bao (2004)]. Previous studies of a French 
cohort find that unemployment of HIV patients is significantly related to health 
related factors such as the number of CD4 cells [Dray-Spira et al. (2007); Dray-
Spira et al. (2005)]. Based on data of a German cohort we aim to analyze drivers 
of unemployment of HIV infected individuals receiving antiretroviral therapy in 
specialized centers in Germany. Methods: We prospectively surveyed 656 HIV 
patients in the age of 18-60 over two years and collected data on potential factors 
that influence the propensity of unemployment (e. g. age, educational background, 
and disease related factors). By means of a logistic regression we identify signifi-
cant determinants of unemployment. Results: The unemployment rate within 
our sample is 29.9% which is much higher than the overall German unemployment 
rate of 6.6%. A poor level of education, concomitant mental diseases, and most of 
all advanced stage of HIV disease significantly determine the likelihood of being 
unemployed. Even controlling for other determinants of unemployment, moving 
from CDC stage A to CDC stage C increases the probability of unemployment 
by 180%. ConClusions: We confirm the results of earlier studies that health 
related factors among HIV patients significantly affects the probability of being 
unemployed. Specifically, the stage of HIV disease seems to be a good predictor of 
unemployment. From a health economic point of view, earlier start of antiretroviral 
treatment and deceleration of disease progression is not only beneficial for the 
patient but also for the economy as a whole.
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objeCtives: Payers, including employers, are struggling to balance cost of novel 
therapies with long-term benefits of the treatments. The goal of this analysis is 
to examine the potential benefit of treating patients with Hepatitis C virus (HCV) 
by evaluating indirect costs during the first year following diagnosis. Methods: 
Employed patients with HCV were identified using the Truven Health Analytics 
Health and Productivity Management Database from 2010-2012. Presence and 
number of days associated with absenteeism (ABS), short-term disability (STD) and 
long-term disability (LTD) were evaluated among patients with HCV and at least 12 
months of continuous enrollment for the year following diagnosis. Costs associated 
with reduced productivity were monetized using an average hourly wage (ABS) and 
a proportion of that wage (70% for STD/LTD) and are reported in US$. Results: A 
total of 3,250 patients met the study inclusion criteria (mean age: 51 years; 67% 
male). Availability of productivity data varied - 588 employees had ABS data, 2,175 
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objeCtives: The prevalence of nosocomial infections is between 5-15%. Reduction 
of nosocomial infections, recognition in time and adequate treatment are all empha-
sised activities of patient security. The aim of this examination is to measure theo-
retical and practical knowledge of hand hygiene of nursing students in secondary 
education. Methods: Cross-sectional qualitative and quantitative was made, with 
non-random, accidental samples in 2014 January with the participation of stu-
dents in secondary nursing education (N= 116) to whom the rules of sepsis, asepsis 
and antisepsis, and correct hand hygiene knowledge were taught according to the 
number of lessons in the curriculum. Self-made opened and closed questionnaires 
were applied, with a focus on the knowledge of hand hygiene. The technique and 
efficiency of hygienic hand disinfection was measured with an infrared lamp. χ 2-
test, t-test, ANOVA were performed as a statistical method besides 95% probability 
(p< 0.05). Data analysis was performed with SPSS 20.0 programs. Results: The con-
cept of disinfection was known correctly by 78% of the students, the exact terminol-
ogy of nosocomial infection was known by 44%. Only 42 students thought that hands 
have the highest relevance in the transfer if infections. The preconditions of proper 
hand hygiene were indicated correctly by 11%. Examination with infrared lamp 
showed that 4 students implemented hand disinfection perfectly. The most common 
missed areas were: the back of the hand, phalanges, nails, thumb. ConClusions: 
Significant reduction of nosocomial infections may and must be reached, to which 
accurate theoretical and practical education of the students is required, and the 
acquirement has to be monitored continuously and strictly.
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objeCtives: To identify and understand the importance of reasons mothers of 
young children would choose to vaccinate their child (ren) against rotavirus and the 
impact of vaccine features on vaccine choice and uptake. Methods: Women with 
children 5 years of age or younger participated in a focus group and semi-structured 
interview to: (1) identify reasons they would choose to vaccinate their children 
against rotavirus independent of the clinical features or cost of the vaccine and (2) 
identify the clinical vaccine features that would influence their decision to vaccinate 
their children. A survey instrument was developed to elicit the relative importance 
of the reasons for vaccination. The survey also included a discrete-choice experi-
ment (DCE) to elicit parents’ preferences for clinical features of hypothetical vac-
cines and likely uptake of vaccines with different clinical features and cost. The 
survey instrument was used in 15 in-depth, face-to-face interviews and the findings 
were used to refine the list of reasons and the clinical vaccine features. Results: 
Study participants identified 7 reasons influencing vaccination decisions – work 
disruptions, child-care disruptions, unplanned expenses, disruptions to routine, 
concern about child’s discomfort, concern about child’s health in the future, concern 
about spreading illness – and 6 clinical vaccine features influencing vaccine choice 
and uptake – number of illnesses prevented, severity of the illnesses prevented, 
duration of illnesses prevented by vaccine, location of vaccination (home or health 
care location), mode of administration (oral or injection), and age at which protec-
tion begins. Cost was also a relevant attribute in these decisions. The reasons for 
vaccination vary with the severity of illness. ConClusions: Deciding to vaccinate 
a child against rotavirus is the result of a decision process that is influenced by 
both the impact of rotavirus on the family, the severity of illness, and the clinical 
characteristics of the vaccine itself.
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objeCtives: To identify a parsimonious factor structure for the 43-item PROQOL-
HIV questionnaire as an easy-to-use instrument for measuring health-related 
quality of life in clinical studies. Methods: Using a representative sample of 
3,022 HIV-infected patients from the Vespa2 French national survey, HRQL was 
summarized using the 8-dimension PROQOL-HIV questionnaire. Exploratory Factor 
Analysis (FA) was used to isolate 4 correlated factors. Dimensionality and internal 
consistency were checked using parallel analysis and Cronbach’s alpha. A con-
firmatory FA was applied on the international validation sample (N= 791, 8 coun-
tries). Summated scale scores were compared to individual scores computed from 
FA and partial credit models. Results: The four dimensions down to: physical 
health and symptoms (11 items, α = 0.931), health concerns and mental distress (10 
items, α = 0.908), social and intimate relationships (7 items, α = 0.898), and treatment 
impact (10 items, α = 0.936). Four items exhibited PROMAX rotated loadings < 0.4, 
three of which were found to cross-load on two factors. This four-factor solution 
suggests acceptable fit to the international validation sample (RMSEA= 0.082, 90% 
CI [0.079; 0.084]; NNFI= 0.880). Correlations between unweighted sum scale scores 
and factor or IRT scores were above 0.9 in most cases. ConClusions: PROQOL-
HIV is the only specific scale taking into account patient’s experience with treat-
ment. This simplified scoring version will allow researchers and clinicians to better 
room visits and hospital admissions. Logistic regressions were constructed to esti-
mate the predictors for resource utilization, and a two-part multivariable analysis 
model was used to determine the total costs of treatment in the UK. Results: Data 
on 731 patients receiving SMV with pegylated interferon and ribavirin (PegIFN/R) 
or PegIFN/R alone were included in the analysis. While MRU was similar between 
SMV and PegIFN/R groups, MRU-related costs were significantly lower in the SMV 
group, compared to the PegIFN/R group (P< 0.05). High body mass index (P< 0.05), 
severe fibrosis (P< 0.05), shortened treatment duration from 48 to 24 weeks (P< 0.05), 
anaemia and rash during treatment (P< 0.001) were identified as predictors of hos-
pitalisation and outpatient visits and as drivers of total costs. Univariate sensitivity 
analyses demonstrated that shortened treatment duration and lower occurrence of 
rash lead to large cost savings. ConClusions: This study identified both baseline 
and on-treatment antiviral therapy characteristics as drivers of MRU-related costs 
for HCV patients following antiviral therapy. The shortened treatment duration and 
reduction in adverse events due to simeprevir treatment lead to extra cost savings 
compared with PegIFN/R treatment. This suggests that there are potential patient 
management and cost-effectiveness implications associated with the choice of 
specific antiviral treatments.
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objeCtives: Willingness-to-pay (WTP) to avoid morbidity is a widely-used meas-
ure of disease valuation. This paper aims to meta-analyze variation in mean-WTP 
of avoiding morbidity due to malaria. Benefits from avoiding incidences can be 
approximated for use in cost-benefit analyses (CBA). This study is an improve-
ment over an earlier meta-analysis: Double-counting is avoided (exclusion of same 
study results), new studies and explanatory variables are added (e. g. malaria 
incidence rates). More sophisticated regression techniques are employed to 
deal with issues, such as heteroscedasticity (e. g. multiple observations from a 
single study). Furthermore, other mosquito-borne diseases (filariasis, trypano-
somiasis and encephalitis) are included to test between-disease valuation dif-
ferences. Methods: A systematic literature review was conducted, resulting in 
a database of 61 studies, yielding 200 data points. A meta-regression model was 
estimated. Dependent variable is mean-WTP per treatment per year in 2012 USD 
(Purchasing Power Parity and inflation adjusted). The explanatory variables con-
sists of (i) treatment characteristics (service, private/public goods etc.), (ii) meth-
odological characteristics (revealed vs. stated preference, WTP elicitation method, 
etc.), and (iii) sample characteristics (age, gender, exposure etc.). Results: 
Standardized mean-WTP range is 0.3 USD and 9000 USD. Data is censored: over 
70% of mean-WTP includes zero-values. Preliminary comparisons show that valu-
ation of malaria avoidance is influenced positively for altruistic interventions and 
negatively for rural samples. The latter is correlated with income- underlining the 
vulnerability of poorer people (due to higher exposure). Additionally, we find sig-
nificantly higher WTP to avoid filariasis over malaria. The meta-regression model 
explains over 30 percent of observed variation between WTP values. Predictive 
power is tested using a jackknife resampling procedure. ConClusions: The 
preliminary results provide policy-makers important information on benefits to 
malaria interventions, with a special focus on rural areas. From a methodological 
perspective, meta-regression helps to improve the practice of benefit transfer, and 
generate improved predictions for CBA.
INfectIoN – Patient-Reported outcomes & Patient Preference studies
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objeCtives: To assess and compare the compliance with anti-HBV antiviral oral 
drugs. Methods: A pharmaco-epidemiological study, based on the IMS LifeLinkTM 
Treatment Dynamics (LTD) database was used to investigate the frequency and 
the regularity of patients’ deliveries on retail pharmacies for 18 months follow-up 
period between June 2012 and November 2013. Incident patients with no anti-
HBV drug deliveries within the last 3 months were included in the cohort. For the 
follow-up period, patients with no anti-HBV deliveries in a retail pharmacy within 
3 consecutive months were considered having stopped their treatment which can 
lead to an overestimation due to the double dispensing system of these drugs 
in France. Study investigated patients’ demographic characteristics, persistence 
rates, medication possession ratio (MPR) and proportion of days covered (PDC) 
according to initial molecule. Results: 793 patients (median age 50 years old) 
initiated a treatment against HBV (patient with both anti-HBV and HIV treatments 
were excluded); for the follow-up period, 5% of patients switched HBV treatment; 
32% of patients stopped their treatment for the follow-up period. Patients who 
continued their treatment are compliant as MPR is respectively of 160% and 103% 
at 6 and 12 months while PDC values are 82% and 78%. No differences stood out 
among the different treatments, especially between Tenofovir and Entecavir (the 
two often prescribed HBV drugs). Moreover older patients tend to be more compli-
ant than the youngest one. ConClusions: By using the IMS Lifelink longitudinal 
database this study highlights the fact that one third of patients treated with anti-
HBV treatment stopped it within 18 months while these drugs are well tolerated. 
Therefore physicians’ challenge consists consequently in motivating patients to 
continue their treatment even they feel asymptomatic.
